Matinas BioPharma Holdings (MTNB) Non-Current Deffered Revenue (2017 - 2018)
Matinas BioPharma Holdings (MTNB) reported Non-Current Deffered Revenue of $512704.0 for Q4 2018, up 12.55% year-over-year from $455554.0 in Q4 2017, and up 2.17% quarter-over-quarter from $501816.0 in Q3 2018.
Matinas BioPharma Holdings (MTNB) Non-Current Deffered Revenue (2017 - 2018) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has 2 years of Non-Current Deffered Revenue data on file, last reported at $512704.0 in Q4 2018.
- Non-Current Deffered Revenue for Q4 2018 came in at $512704.0, up 12.55% year-over-year; the trailing twelve-month figure through Dec 2018 was $512704.0 (up 12.55% YoY), and the FY2018 annual result was $512704.0, up 12.55% from the prior year.
- Non-Current Deffered Revenue climbed to $512704.0 in Q4 2018 per MTNB's latest filing, from $501816.0 in the prior quarter.
- Over five years, Non-Current Deffered Revenue peaked at $512704.0 in Q4 2018 and troughed at $455554.0 in Q4 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Matinas BioPharma Holdings | 4.60 Mn | 2.15 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 512,704.00 |
| Sep 30, 2018 | 501,816.00 |
| Jun 30, 2018 | 489,161.00 |
| Mar 31, 2018 | 472,480.00 |
| Dec 31, 2017 | 455,554.00 |